Evidence map›Paper›PMID 39792431›Full record

ArticleSchizophrenia bulletin2025

Development and Validation of a Brief Age-Normed Screening Tool for Subthreshold Psychosis Symptoms in Youth.

Monica E Calkins, Arielle Ered, Tyler M Moore, Lauren K White, Jerome Taylor, Alexander B Moxam, Kosha Ruparel, Daniel H Wolf, Theodore D Satterthwaite, Christian G Kohler and 2 more

Abstract readValidation Study
In one paragraph

Article in Schizophrenia bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Monica E CalkinsDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-0546-0263
Arielle EredDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-8386-4423
Tyler M MooreDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Lauren K WhiteDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Jerome TaylorDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Alexander B MoxamDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Kosha RuparelDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Daniel H WolfDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Theodore D SatterthwaiteDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Christian G KohlerDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Ruben C GurDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Raquel E GurDepartment of Psychiatry, Neurodevelopment and Psychosis Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Funding

Neurodevelopmental Genomics: Trajectories of Complex PhenotypesRC2MH089983 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 2009 to 2011
$14.3M
2/2 Neurodevelopmental Genomics: Trajectories of Complex PhenotypesRC2MH089924 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI HAKONARSON, HAKON · 2009 to 2011
$10.7M
Longitudinal Mapping of Network Development Underlying Executive Dysfunction in AdolescenceR01MH113550 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Danielle Smith Bassett, Theodore Satterthwaite · 2018 to 2026
$6.9M
SCHIZOPHRENIA: A NEUROPSYCHIATRIC PERSPECTIVET32MH019112 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 1990 to 2024
$6.2M
Inter-modal Coupling Image AnalyticsR01MH112847 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Theodore Satterthwaite, Russell Takeshi Shinohara · 2017 to 2026
$5.9M
Evolution of Psychosis in Youth: Multimodal Risk and Resilience MarkersR01MH119219 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E, GUR, RUBEN C. · 2019 to 2023
$3.8M
Reproducible imaging-based brain growth charts for psychiatryR01MH120482 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI MILHAM, MICHAEL PETER, SATTERTHWAITE, THEODORE · 2019 to 2023
$3.5M
A Prospective Study of Endophenotypes in At-Risk Youths and Their SiblingsK08MH079364 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI CALKINS, MONICA E · 2007 to 2011
$750k
Lifespan Brain Institute MH119219Lifespan Brain Institute R01MH112847Lifespan Brain Institute R01MH113550Lifespan Brain Institute R01MH120482NIMH NIH HHS K08 MH079364NIMH NIH HHS K08MH079364NIMH NIH HHS L30 MH137813NIMH NIH HHS MH089924NIMH NIH HHS MH089983NIMH NIH HHS R01 MH112847NIMH NIH HHS R01 MH113550NIMH NIH HHS R01 MH119219NIMH NIH HHS R01 MH120482NIMH NIH HHS RC2 MH089924NIMH NIH HHS RC2 MH089983NIMH NIH HHS T32 MH019112NIMH NIH HHS T32MH019112
6 · The paper itself

Abstract

background and hypothesisImprovements in screening tools for early subthreshold psychosis symptoms are needed to facilitate early identification and intervention efforts, especially given the challenges of rapidly differentiating age-appropriate experiences from potential early signs of emerging psychosis. Tools can be lengthy and time-consuming, impacting their utility and accessibility across clinical settings, and age-normed data are limited. To address this gap, we sought to develop and validate a brief, empirically derived, age-normed, subthreshold psychosis screening tool, for public use. STUDY

designComputerized adaptive test simulation was used to derive a 5-item short form with age norm equivalencies from a 12-item PRIME-Screen-Revised (PRIME-12) administered to 7053 youth (Mage = 15.8, SD = 2.7; 54% female; 33% Black). Concurrent validity was assessed (n = 758) using contemporaneous administration of the PRIME-5 and the Structured Interview for Prodromal Syndromes. Comparability of criterion-related validity of the PRIME-5, PRIME-12, and Scale of Prodromal Symptoms (SOPS) was assessed by relating scores to psychosis-risk-relevant criteria. Finally, self-report versus assessor-administered PRIME total scores were compared (n = 131) to assess their concurrent validity. STUDY

resultsCorrelations among PRIME-5, PRIME-12, and SOPS were comparable and moderate, supporting their convergent validity. The PRIME-5 also showed comparable criterion-related validity, demonstrating similar relationships with psychosis-risk indicators as the other tools. Self-reported and assessor-administered PRIME-5 were moderately correlated.

conclusionsPublic availability of a brief, age-normed, and validated screening tool-which can be assessor or self-administered-will expedite and improve early identification of youth (age 11 and older) at risk for psychosis.

Indexed as

Prodromal SymptomsPsychiatric Status Rating ScalesPsychometricsPsychotic DisordersAdolescentAdultChildFemaleHumansMaleReproducibility of ResultsYoung Adultage-normedcommunity youthpsychosis-spectrum symptomssubthreshold psychosis screen

Identifiers

PMID39792431
PMCPMC12414555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.